Crohn’s & Colitis Foundation Visiting IBD Fellowship 2018-2019

Professional Education Resources & Reading List 2018

Virtual Preceptorship ..................... 1
ReachMD Resources ...................... 2
Biosimilars Resources ..................3
Professional Reading list ...............4 - 6
VIRTUAL PRECEPTORSHIP (Online Accredited Interactive Case Modules)

**IBD in Clinical Practice: Malnutrition Update for Healthcare Providers**

In this CME online activity, you will learn the importance of malnutrition for IBD patients and how to apply important elements of the Foundation’s IBD Nutrition Care Pathway -- a tool that is useful for the screening, evaluation, intervention, and monitoring for patients with IBD and malnutrition.

*This activity is jointly provided by Postgraduate Institute for Medicine, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC. This activity is supported by an independent medical educational grant from Nestlé Health Science.*

**IBD in Clinical Practice: Anemia**

In this CME online activity you will learn how to apply important elements of the Foundation’s IBD Anemia Care Pathway -- a tool that is useful for the screening, evaluation, intervention, and follow up of patients with IBD and iron deficiency. Also in this activity you will hear a testimonial from Lyn, an IBD patient with iron deficiency, as she recounts interesting aspects of her history and treatments.

*This activity is jointly provided by Postgraduate Institute for Medicine, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC. This activity is supported by an independent medical educational grant from Luitpold Pharmaceuticals.*
New Educational Resources for Healthcare Professionals

The Crohn's & Colitis Foundation has partnered with ReachMD, the nation's largest medical education learning platform for healthcare professionals, to deliver exclusive IBD content. Watch expert interviews on IBD topics through the Crohn's & Colitis Perspectives educational series, and listen to short audio distillations of articles from the Inflammatory Bowel Diseases Journal through ReachMD's AudioAbstracts™.

Access these great resources at: ReachMD.com/Foundation
Comprehensive Update of Biosimilar Therapies

The Crohn’s & Colitis Foundation and American Gastroenterological Association (AGA) are pleased to provide several CME educational resources for professionals to ensure accurate and unbiased information about biosimilars. This program is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc.

On-demand Online Activities:

- **CME Video** *Advent of Biosimilar Products in US GI Practice*—learn how biosimilars are used in the practice of gastroenterology in the US
- **CME Video** *Consideration in the Use of Biosimilars for Gastrointestinal Disorders*—overview of the current body of knowledge on the safety and efficacy of biosimilar products, pricing and impact of payor decisions on clinical GI practice
- **CME Video** *Talking to your IBD Patient about Biosimilar Therapies*—best practices for how to converse with patients on biosimilars
- **CME Module** *U.S. FDA Regulatory Pathway for Biosimilars*—an overview of how biosimilars are licensed in the U.S., exploring interchangeability and data extrapolation
- **Webcast** *Comprehensive Update of Biosimilar Therapies: Your Questions Answered*—updates on biosimilars from Dr. Gary R. Lichtenstein and engaging interactive panel with Drs. Brian G. Feagan, David T. Rubin and a patient

Access and learn more at: www.crohnscolitisfoundation.org/science-and-professionals/biosimilars.html
Professional Reading List 2018

**Section: Practice Guidelines**

**Clinical Practice Guidelines for the Medical Management of Nonhospital zed Ulcerative Colitis: The Toronto Consensus**  
Bressler B1, Marshall JK2, Bernstein CN3, Bitton A4, Jones J5, Leontiadis GI6, Panaccione R7, Steinhart AH8, Tse F9, Feagan B8;  
**Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.** Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M et al.

**Section: Treatment Strategies**

**Treat to Target: A Proposed New Paradigm for the Management of Crohn’s Disease.**  
**The management of immunosuppression in patients with inflammatory bowel disease and cancer.**  
Bernheim O1, Colombel JF, Ullman TA, Laharie D, Beaugerier L, Itzkowitz SH.  
*Gut.* 2012 Feb; 61(2):229-34.  
**Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomized SWITCH trial.**  

**Section: Treatment/Biologics**

**Vedolizumab as induction and maintenance therapy for Crohn’s disease.**  
**Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.**  
Travis SP, Danese S, Kupcinskas L, Alexeeva O, D’Haens G, Gibson PR et al.  
**Infliximab for induction and maintenance therapy for ulcerative colitis.**  
**Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.**  
*Gastroenterology.* 2014;146(1):85-95;  
**Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.**  

Section: New Therapies
Therapeutic Advances in Gastroenterology. 2015;8(2):66-82.
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therapeutic advances in gastroenterology.
Amiot A, Peyrin-Biroulet L.

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.


The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Soetikno R1, Subramanian V, Kaltenbach T, Rouse RV, Sanduleanu S, Suzuki N, Tanaka S, McQuaid K.


Section: Imaging/Diagnostics
The treatment-naive microbiome in new-onset Crohn's disease.
Gevers D1, Kugathasan S2, Denson LA3, Vázquez-Baeza Y4, Van Treuren W5, Ren B6, Schwager E6, Knights D7, Song SJ5, Yassour M5, Morgan XC6, Kostic AD7, Luo C8, González A9, McDonald D8, Haberman Y9, Walters T9, Baker S9, Rosh J10, Stephens.
Diet rapidly and reproducibly alters the human gut microbiome.


Selected Topics: Extraintestinal Manifestations

Extraintestinal manifestations and complications in IBD. Nature reviews
Ott C, Scholmerich J.

Selected topics: Pouch

Clinical value of surveillance pouchoscopy in asymptomatic ileal pouch patients with underlying inflammatory bowel disease. Zhu H¹, Wu XR, Queener E, Kiran RP, Remzi FH, Shen B.

Evaluating pouch problems.
Li Y¹, Shen B.

Selected topics: Health Maintenance

Health maintenance in the inflammatory bowel disease patient.
Sinclair JA, Wasan SK, Farraye FA.

Selected topics: Epidemiology

Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN.

Selected topics: Postoperative Crohn’s

American Gastroenterological Association Institute Guideline on the Management of Crohn’s Disease After Surgical Resection.
Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S;

Regueiro M, Velayos F, Greer JB, Bougatsos C, Chou R, Sultan S, Singh S.

Gastroenterology. 2016 Jun; 150(7):1568-78.
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection.